Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	274.16	232.19	222.95	241.58	848.63	347.82
Short-Term Investments	202.14	234.83	682.4	1,281	1,553	360.33
Cash & Short-Term Investments	476.3	467.02	905.35	1,522	2,402	708.15
Cash Growth	-40.59%	-48.42%	-40.53%	-36.62%	239.20%	-3.90%
Other Receivables	-	-	-	-	-	773.08
Total Trade Receivables	-	-	-	-	-	773.08
Other Current Assets	46.69	47.07	137.11	65.82	117.04	81.6
Total Current Assets	522.99	514.08	1,042	1,588	2,519	1,563
Net Property, Plant & Equipment	113.92	117.72	122.86	167.2	188.17	130.05
Other Intangible Assets	7.78	7.85	8.12	22.57	32.76	33.29
Goodwill	16.94	16.94	16.94	16.94	16.94	16.94
Long-Term Investments	332.97	314.58	190.02	105.28	23.93	201.39
Other Long-Term Assets	31	31.66	18.42	18.86	21.23	9.78
Total Assets	1,026	1,003	1,399	1,919	2,802	1,954
Accounts Payable	5.45	9.8	5.08	6.33	6.42	6.52
Accrued Expenses	68.11	83.01	98.52	104.22	489.09	236.51
Unearned Revenue	-	-	-	64.85	15.52	98.21
Other Current Liabilities	-	-	16.06	-	-	-
Total Current Liabilities	73.56	92.82	119.66	175.41	511.03	341.24
Long-Term Leases	86.64	89.05	90.14	111.67	123.84	133.56
Other Long-Term Liabilities	52.63	55.68	38.63	41.74	89.26	47.62
Total Long-Term Liabilities	139.26	144.73	128.77	153.42	213.1	181.18
Total Liabilities	212.82	237.55	248.43	328.82	724.13	522.42
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	2,140	1,965	1,912	1,829	1,710	1,572
Accumulated Other Comprehensive Income	-3.48	-2.06	-1.72	-0.82	-9.12	-1.1
Retained Earnings	-	-	-	-237.82	377.24	-138.6
Shareholders' Equity	2,136	1,963	1,910	1,590	2,078	1,432
Total Liabilities & Equity	1,026	1,003	1,399	1,919	2,802	1,954
Total Debt	86.64	89.05	90.14	111.67	123.84	133.56
Net Cash (Debt)	389.66	377.96	815.21	1,411	2,278	574.58
Net Cash Growth	3.10%	-53.64%	-42.21%	-38.08%	296.50%	-14.28%
Net Cash Per Share	2.76	2.73	5.98	10.52	16.90	4.31
Book Value	2,136	1,963	1,910	1,590	2,078	1,432
Book Value Per Share	15.15	14.17	14.02	11.86	15.41	10.73
Tangible Book Value	2,112	1,938	1,885	1,551	2,028	1,382
Tangible Book Value Per Share	14.98	13.99	13.84	11.56	15.05	10.35

SEC Filings: 10-K · 10-Q